Skip to main content
SpringerLink
Log in

Abnormal Uterine Bleeding

  • Chapter
  • First Online:
Progestogens in Obstetrics and Gynecology

  • 437 Accesses

Abstract

One of the most common gynecological consultations is for abnormal uterine bleeding. The condition accounts for up to 70% of new gynecological consultations in perimenopausal women. After excluding organic causes, the mainstay of treatment is medical, most usually with progestogen supplementation. However, treatment should be personalized depending on the patients age, desire for contraception or fertility, etc. In many cases in addition to progestogen, estrogen is often required to build the endometrium, particularly in cases of a thinned endometrium due to ovarian dysfunction. Thus, the choice of progestogen needs to take into account the estrogenic, antiestrogenic, androgenic or anti-androgenic effects of the particular progestogen. In this chapter the pathophysiology, diagnosis and the resulting medical treatments of abnormal uterine bleeding are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22:635–43.

    Article  PubMed  Google Scholar 

  2. Royal College of Obstetricians and Gynaecologists. National menstrual heavy bleeding audit. Second annual report. London: Royal College of Obstetricians and Gynaecologists; 2012. www.rcog.org.uk

    Google Scholar 

  3. Munro MG, Critchley HOD, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynecol Obstet. 2011;113:3–13.

    Article  Google Scholar 

  4. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011;18:408–11.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Krikun G, Schatz F, Lockwood CJ. Endometrial angiogenesis: From physiology to pathology. Ann N Y Acad Sci. 2004;1034:27–35.

    Article  CAS  PubMed  Google Scholar 

  6. Schatz F, Krikun G, Caze R, Rahman M, Lockwood CJ. Progestin-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. Steroids. 2003;68(10):849–60.

    Article  CAS  PubMed  Google Scholar 

  7. Pan H, Deng Y, Pollard JW. Progesterone blocks estrogen-induced DNA synthesis through the inhibition of replication licensing. Proc Natl Acad Sci USA. 2006;103:14021–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lockwood CJ, Nemerson Y, Guller S, Krikun G, Alvarez M, Hausknecht V, et al. Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization. J Clin Endocrinol Metab. 1993;76:231–6.

    CAS  PubMed  Google Scholar 

  9. Lockwood CJ, Murk W, Kayisli UA, Buchwalder LF, Huang ST, Funai EF, et al. Progestin and thrombin regulate tissue factor expression in human term decidual cells. J Clin Endocrinol Metab. 2009;94:2164–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zini JM, Murray SC, Graham CH, Lala PK, Kariko K, Barnathan ES, et al. Characterization of urokinase receptor expression by human placental trophoblasts. Blood. 1992;79:2917–29.

    Article  CAS  PubMed  Google Scholar 

  11. Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium. Early Pregnancy. 2000;4:230–9.

    CAS  PubMed  Google Scholar 

  12. Critchley HOD, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams ARW, et al. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab. 1999;84:240–8.

    CAS  PubMed  Google Scholar 

  13. Baird DT, Cameron ST, Critchley HOD, Drudy TA, Howe A, Jones RL, et al. Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol. 1996;70:15–7.

    Article  CAS  PubMed  Google Scholar 

  14. Critchley HOD, Kelly RW, Brenner RM, Baird DT. The endocrinology of menstruation - A role for the immune system. Clin Endocrinol. 2001;55:701–10.

    Article  CAS  Google Scholar 

  15. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound. 1993;21(2):87–95.

    Article  CAS  PubMed  Google Scholar 

  16. Epstein E, Ramirez A, Skoog L, Valentin L. Transvaginal sonography, saline contrast sonohysterography and hysteroscopy for the investigation of women with postmenopausal bleeding and endometrium > 5 mm. Ultrasound Obstet Gynecol. 2001;18:157–62.

    Article  CAS  PubMed  Google Scholar 

  17. Nieuwenhuis LL, Hermans FJR, Bij de Vaate AJM, Leeflang MMG, Brölmann HAM, Hehenkamp WJK, et al. Three-dimensional saline infusion sonography compared to two-dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions. Cochrane Database Syst Rev. 2017;5(5):CD011126.

    PubMed  Google Scholar 

  18. Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002;1(86):409–15.

    Article  Google Scholar 

  19. Justin Clark T, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: A systematic quantitative review. J Am Med Assoc. 2002;288:1610–21.

    Article  Google Scholar 

  20. Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: Management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152:133–7.

    Article  CAS  PubMed  Google Scholar 

  21. Rodriguez GC, Yaqub N, King ME. A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol. 1993;168:55–9.

    Article  CAS  PubMed  Google Scholar 

  22. Yarandi F, Izadi-Mood N, Eftekhar Z, Shojaei H, Sarmadi S. Diagnostic accuracy of dilatation and curettage for abnormal uterine bleeding. J Obstet Gynaecol Res. 2010;36:1049–52.

    Article  PubMed  Google Scholar 

  23. Demirkiran F, Yavuz E, Erenel H, Bese T, Arvas M, Sanioglu C. Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage (D&C). Arch Gynecol Obstet. 2012;286:1277–82.

    Article  PubMed  Google Scholar 

  24. Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obstet Gynecol. 2009;201:5–11.

    Article  PubMed  Google Scholar 

  25. James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol. 2004;104(2):381–8.

    Article  PubMed  Google Scholar 

  26. March CM. Bleeding problems and treatment. Clin Obstet Gynecol. 1998;41:928–39.

    Article  CAS  PubMed  Google Scholar 

  27. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982;59:285–91.

    CAS  PubMed  Google Scholar 

  28. Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108:924–9.

    Article  CAS  PubMed  Google Scholar 

  29. American College of Obstetricians and Gynecologists. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. The American College of Obstetricians and Gynecoly. Committee Opinion No. 557. Obstet Gynecol. 2013;121:891–6.

    Article  CAS  Google Scholar 

  30. Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: A pilot study. Am J Obstet Gynecol. 2013;208:499.

    Article  PubMed  CAS  Google Scholar 

  31. Klehr-Bathmann I, Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas. 1995;21:245–50.

    Article  CAS  PubMed  Google Scholar 

  32. Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 1997;56:379–85.

    Article  CAS  PubMed  Google Scholar 

  33. Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. J Fam Plann Reprod Health Care. 2012;38:148–9.

    Article  PubMed  Google Scholar 

  34. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007;92:2205–7.

    Article  CAS  PubMed  Google Scholar 

  35. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kuhl H, Wiegratz I. Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications? Climacteric. 2007;10:344–53.

    Article  CAS  PubMed  Google Scholar 

  37. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen only contraception in women at high risk of venous thromboembolism. Contraception. 2004;70:437–41.

    Article  CAS  PubMed  Google Scholar 

  38. Gompel A, Carpentier S, Francès C, Piette JC. Risk of venous thromboembolism and oral contraceptives. Lancet. 2002;359:1348–9.

    Article  CAS  PubMed  Google Scholar 

  39. Fulghesu AM, Magnini R, Piccaluga MP, Porru C. Ovulation induction in young girls with menometrorragia: a safe and effective treatment. Gynecol Endocrinol. 2014;30:117–20.

    Article  CAS  PubMed  Google Scholar 

  40. De Francicis P, Cobellis L, Fornaro F, Sepe E, Torella M, Colacurci N. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet. 2007;98:138–42.

    Article  CAS  Google Scholar 

  41. Karakus S, Kiran G, Ciralik H. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Aust N Z J Obstet Gynaecol. 2009;49:685–8.

    Article  PubMed  Google Scholar 

  42. Toppozada HK, S.Koetsawang S, Aimakhu VR, Khan T, Pretnar-Darovec A, et al. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28:1–20.

    Google Scholar 

  43. Benetti-Pinto CL, Rosa-E-Silva ACJS, Yela DA, Soares Júnior JM. Abnormal Uterine Bleeding. Rev Bras Ginecol Obstet. 2017;39:358–68.

    Article  PubMed  Google Scholar 

  44. Archer DF, Merkatz RB, Bahamondes L, Westhoff CL, Darney P, Apter D, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health. 2019;7:1054–64.

    Article  Google Scholar 

  45. Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs. 2012;72:193–215.

    Article  CAS  PubMed  Google Scholar 

  46. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2011;18:75–80.

    Article  PubMed  Google Scholar 

  47. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655–62.

    Article  PubMed  Google Scholar 

  48. Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012;124:542–8.

    Article  PubMed  Google Scholar 

  49. Campagnoli C, Abba C, Ambroggio S, Brucato T, Pasanisi P. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol. 2013;29:119–24.

    Article  PubMed  Google Scholar 

  50. Tasci Y, Polat OG, Ozdogan S, Karcaaltincaba D, Seckin L, Erkaya S. Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet. 2014;290:83–6.

    Article  CAS  PubMed  Google Scholar 

  51. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel- releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203:547.

    Article  PubMed  CAS  Google Scholar 

  52. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of food and drug administration experience and a review of the literature. Arch Intern. Med. 1997;157:1651–6.

    Article  CAS  PubMed  Google Scholar 

  53. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171–80.

    Article  PubMed  Google Scholar 

  54. Mesci-Haftaci S, Ankarali H, Yavuzcan A, Caglar M. Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia. Asian Pac J Cancer Prev. 2014;15:3737–40.

    Article  PubMed  Google Scholar 

  55. Meden-Vrtovec H, Hren-Bozic M. Glandular cystic hyperplasia of the endometrium in the perimenopausal years. Acta Eur Fertil. 1988;19:49–52.

    CAS  PubMed  Google Scholar 

  56. El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, Mohamed Mei S. Levonorgestrel-releasing Intrauterine device versus Dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015;22:329–34.

    Article  PubMed  CAS  Google Scholar 

  57. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. 2013;28:2966–71.

    Article  CAS  PubMed  Google Scholar 

  58. Abu Hashim H, Zayed A, Ghayaty E, El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013;24:128–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ismail MT, Fahmy DM, Elshmaa NS. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod Sci. 2013;20:45–50.

    Article  CAS  PubMed  Google Scholar 

  60. Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7:2534–6.

    PubMed  PubMed Central  Google Scholar 

  61. Godha Z, Mohsin Z, Hakim S, Wasim S. Comparative study of Ormeloxifene and Medroxyprogesterone acetate in abnormal uterine bleeding. J Obstet Gynaecol India. 2016;66(Suppl 1):395–9.

    Article  CAS  PubMed  Google Scholar 

  62. Bouchard P. Current and future medical treatments for menometrorrhagia during the premenopause. Gynecol Endocrinol. 2011;27(Suppl 1):1120–5.

    Article  CAS  PubMed  Google Scholar 

  63. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22:1696–704.

    Article  CAS  PubMed  Google Scholar 

  64. Lethaby A, Duckitt K, Farquhar C. Non-steroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;1:CD000400.

    Google Scholar 

  65. Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai. 2004;87(Suppl 3):S64–8.

    PubMed  Google Scholar 

  66. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112:1121–5.

    Article  PubMed  Google Scholar 

  67. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;4:CD000249.

    Google Scholar 

  68. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:865–75.

    Article  PubMed  Google Scholar 

  69. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86:714–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    Eran Zilberberg & Howard J. A. Carp

  2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Howard J. A. Carp

Authors
  1. Eran Zilberberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard J. A. Carp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard J. A. Carp .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Howard J.A. Carp

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zilberberg, E., Carp, H.J.A. (2021). Abnormal Uterine Bleeding. In: Carp, H.J. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-030-52508-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52508-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52507-1

  • Online ISBN: 978-3-030-52508-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation